Background: Several trials and meta-analyses have recently demonstrated the superiority of endovascular therapy over standard medical treatment in patients presenting with acute ischemic stroke. In order to offer the best possible treatment to a maximum number of patients, many stroke care networks probably have to be reorganized. After analyzing the reliability of data in the literature, an algorithm is suggested for a pre-hospital and in-hospital alert system to improve the timeliness of subsequent treatment: a drip-and-ship approach. Summary: Five recent well-designed randomized studies have demonstrated the benefit of endovascular therapy associated with intravenous fibrinolysis by recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke with confirmation by recent meta-analyses. The keys for success are a very short time to reperfusion, within 6 h, a moderate to severe pre-treatment deficit (National Institute of Health around 17), cerebral imaging able to identify proximal large vessel occlusion in the anterior circulation, a limited infarct core and a reversible penumbra, the use of the most recent devices (stent retriever) and a procedure that avoids general anesthesia, which reduces blood pressure. To meet these goals, every country must build a national stroke infrastructure plan to offer the best possible treatment to all patients eligible for intravenous fibrinolysis and endovascular therapy. The plan may include the following actions: inform the population about the first symptoms of stroke, provide the call number to improve the timeliness of treatment, increase the number of comprehensive stroke centers, link these to secondary and primary stroke centers by telemedicine, teach and train paramedics, emergency doctors and radiologists to identify the stroke infarct, proximal large vessel occlusion and the infarct core quickly, train a new generation of endovascular radiologists to improve access to this therapy. Key Message: After 20 years of rt-PA, this new evidence-based therapy is a revolution in stroke medicine that will benefit patients. However, a new robust and multi-disciplinary care strategy is necessary to transfer the scientific data into clinical practice. It will require reorganization of the stroke infrastructure, which will include comprehensive stroke centers and secondary and primary stroke centers. The winners will be patients with severe stroke.

Keywords:
Ischemic stroke, Fibrinolysis, Stroke networks, Stent retriever, Endovascular treatment
1.
Giroud M, Jacquin A, Béjot Y: The worldwide landscape of stroke in the 21st century. Lancet 2014;383:195-197.
2.
Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med 1995;333:1581-1587.
3.
Jauch EC, Saver JL, Adams HP Jr, et al: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
4.
Riedel CH, Zimmermann P, Jensen-Kondering U, et al: The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011;42:1775-1777.
5.
Lima FO, Furie KL, Silva GS, et al: Prognosis of untreated strokes due to anterior circulation proximal intracranial arterial occlusions detected by use of computed tomography angiography. JAMA Neurol 2014;71:151-157.
6.
Ogawa A, Mori E, Minematsu K, et al: Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007;38:2633-2639.
7.
Mazighi M, Serfaty JM, Labreuche J, et al: Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009;8:802-809.
8.
Ciccone A, Valvassori L, Nichelatti M, et al; SYNTHESIS Expansion Investigators: Endovascular treatment for acute ischemic stroke. N Engl J Med 2013;368:904-913.
9.
Kidwell CS, Jahan R, Gornbein J, et al; MR RESCUE Investigators: A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368:914-923.
10.
Broderick JP, Palesch YY, Demchuk AM, et al; Interventional Management of Stroke (IMS) III Investigators: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893-903.
11.
Fransen PS, Beumer D, Berkhemer OA, et al; MR CLEAN Investigators: MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in The Netherlands: study protocol for a randomized controlled trial. Trials 2014;15:343.
12.
Berkhemer OA, Fransen PS, Beumer D, et al; MR CLEAN Investigators: A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11-20.
13.
Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators: Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019-1030.
14.
Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators: Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009-1018.
15.
Saver JL, Goyal M, Bonafe A, et al; SWIFT PRIME Investigators: Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285-2295.
16.
Jovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators: Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296-2306.
17.
Campbell BC, Donnan GA, Lees KR, et al: Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurol 2015;14:846-854.
18.
Badhiwala JH, Nassiri F, Alhazzani W, et al: Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. JAMA 2015;314:1832-1843.
19.
Prabhakaran S, Ruff I, Bernstein RA: Acute stroke intervention: a systematic review. JAMA 2015;313:1451-1462.
20.
Chen CJ, Ding D, Starke RM, et al: Endovascular vs medical management of acute ischemic stroke. Neurology 2015;85:1980-1990.
21.
Spiotta AM, Vargas J, Turner R, et al: The golden hour of stroke intervention: effect of thrombectomy procedural time in acute ischemic stroke on outcome. J Neurointerv Surg 2014;6:511-516.
22.
Sheppard JP, Mellor RM, Greenfield S, et al: The association between prehospital care and in-hospital treatment decisions in acute stroke: a cohort study. Emerg Med J 2015;32:93-99.
23.
Jung S, Stapf C, Arnold M: Stroke unit management and revascularisation in acute ischemic stroke. Eur Neurol 2015;73:98-105.
24.
Furlan AJ: Endovascular therapy for stroke - it's about time. N Engl J Med 2015;372:2347-2349.
25.
Liman TG, Winter B, Waldschmidt C, et al: Telestroke ambulances in prehospital stroke management: concept and pilot feasibility study. Stroke 2012;43:2086-2090.
26.
Goyal M, Menon BK, Coutts SB, et al: Effect of baseline CT scan appearance and time to recanalization on clinical outcomes in endovascular thrombectomy of acute ischemic strokes. Stroke 2011;42:93-97.
27.
Grotta J, Hacke W: Stroke neurologist's perspective on the new endovascular trials. Stroke 2015;46:1447-1452.
28.
Smith EE, Schwamm LH: Endovascular clot retrieval therapy: implications for the organization of stroke systems of care in North America. Stroke 2015;46:1462-1467.
29.
Jauch EC, Saver JL, Adams HP Jr, et al: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
30.
Hervieu-Begue M, Jacquin A, Osseby GV, et al: The role of the clinical nurse within a combined stroke and telefibrinolysis network: the G5 pilot study in Burgundy, France. Eur Res Telemed 2013;2:11-15.
31.
Raffe F, Jacquin A, Milleret O, et al: Evaluation of the possible impact of a care network for stroke and transient ischemic attack on rates of recurrence. Eur Neurol 2011;65:239-244.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.